Kalshi is Betting on Trial Results and FDA Decisions Now, What's Next?
FDA Announces 3 Final Guidances to Increase Patient Participation in Oncology Trials
Evis Sala Announces a Landmark Oncology Partnership Between Albania and Italy
Wafik El-Deiry: Scientific Freedom and Diverse Thinking Drive Better Medicine
RxPONDER Analysis: Ovarian Reserve May Refine Chemotherapy Decisions in HR-Positive Breast Cancer
First Chemotherapy Session: What to Expect
Herbert Loong: Prospective Open-labelled Phase 2 Pembrolizumab in Acral Lentiginous Melanoma
SABCS 2026 Male Breast Cancer Advocate Scholarship
Tracks percentage of skeletal tumor burden and change from baseline in metastatic bone disease, for longitudinal monitoring of disease trend.
Trend thresholds: Stable within ±10% of baseline | Increase >10% | Decrease >10%
The Bone Scan Index (BSI) is a quantitative imaging measure used to estimate skeletal tumour burden on bone scintigraphy. It is most commonly discussed in metastatic prostate cancer, where bone is a frequent site of disease spread.
The OncoDaily Bone Scan Index Tracker helps users document and compare BSI values that have already been reported by a validated imaging platform or nuclear medicine assessment. It does not read bone scan images or diagnose bone metastases. Instead, it supports structured tracking of baseline and current BSI values over time.
The Bone Scan Index is a quantitative imaging biomarker used to estimate the extent of suspected metastatic disease in the skeleton on a radionuclide bone scan. A BSI result is generally expressed as the estimated percentage of total skeletal mass affected by metastatic-appearing lesions. It translates bone-scan findings into a numerical estimate of skeletal tumour burden rather than relying only on a descriptive report.
Terms such as BSI calculator and BSI score calculator are often used when referring to software-based tools that identify suspicious hotspots and calculate the Bone Scan Index. These are not manual calculators for patients or clinicians to use independently. A higher Bone Scan Index may indicate a greater burden of skeletal metastatic disease. However, the score should always be interpreted alongside the original scan, clinical findings, PSA level, laboratory results, other imaging, and treatment history.
OncoDaily’s tool functions as a BSI tracker, not as software that reads or interprets bone scan images directly. It allows users to enter a current BSI value, compare it with a baseline BSI value, and document whether the reported skeletal tumour burden appears to increase, decrease, or remain stable over time.
This can support structured follow-up in metastatic prostate cancer by making BSI values easier to compare across treatment visits. The tracker is designed for longitudinal documentation and should not replace a validated image-based BSI platform, radiology interpretation, or oncology decision-making.
Current BSI refers to the most recent Bone Scan Index value available for a patient. This value may come from a bone scan report, an AI-assisted bone scan assessment, or a nuclear medicine evaluation that provides a documented BSI score. In the OncoDaily tracker, the current BSI is entered as the latest available measurement of skeletal tumour burden. It is then compared with the baseline BSI to help show whether the documented burden has increased, decreased, or remained stable. The current BSI should come from a validated clinical source. It should not be estimated visually by a user or entered as a guess based on how a scan appears.
Baseline BSI is the earlier Bone Scan Index value used as the reference point for comparison with later assessments. It may be recorded at diagnosis of metastatic disease, before starting systemic treatment, or before beginning a new line of therapy. The most appropriate baseline depends on the clinical question. A pre-treatment BSI may be useful when assessing response to first-line therapy, while a value obtained before a treatment change may be more relevant when monitoring a later-line regimen.
BSI change shows the difference between the current Bone Scan Index and the baseline BSI value. Across serial scans, this comparison can help indicate whether the documented skeletal disease burden is increasing, decreasing, or remaining relatively stable. A rising BSI may suggest greater skeletal involvement, while a falling BSI may be consistent with reduced measurable skeletal tumour burden.
However, trend is often more useful than one isolated BSI number. Changes should always be interpreted alongside the imaging report, PSA kinetics, symptoms, laboratory findings, treatment timing, and other imaging results.
The Bone Scan Index is usually calculated from bone scintigraphy images by identifying suspicious hotspots, estimating the proportion of skeletal mass involved, and converting this information into a percentage-based measure of skeletal disease burden. Advanced BSI systems use automated or AI-supported image analysis to detect hotspots, classify their likely significance, and calculate the final score. OncoDaily’s tracker does not calculate BSI directly from images. Instead, it helps clinicians and patients document and compare BSI values that are already available from validated bone scan reports or image-analysis platforms.
Bone scan hotspots are areas with increased uptake of the radiotracer, reflecting increased bone turnover or activity. In metastatic prostate cancer, some hotspots may represent bone metastases. However, not every hotspot is cancer. Degenerative joint disease, recent trauma or fractures, inflammation, infection, and other benign conditions can also produce increased uptake. For this reason, hotspots should be interpreted by nuclear medicine specialists or radiologists in combination with scan pattern, CT or MRI findings when available, clinical history, symptoms, PSA trend, and other relevant laboratory results.
Automated Bone Scan Index tools, such as aBSI, use AI or software-based image analysis to detect, categorize, and quantify suspicious skeletal hotspots on bone scintigraphy. Compared with manual visual counting alone, these systems are designed to support a more standardized assessment of skeletal tumour burden. Commercial BSI platforms emphasize accuracy, quantification, and reproducibility.
In practice, software may pre-select hotspots, calculate an estimated BSI, and update the score when the interpreting clinician edits or confirms selected findings. Final interpretation still requires qualified clinical review because automated analysis cannot independently determine whether every hotspot represents metastatic disease.
Automated BSI results should always be reviewed by a nuclear medicine physician, radiologist, and the treating oncology team. Imaging findings must be interpreted alongside clinical history, symptoms, prior scans, PSA or other relevant tumour markers, laboratory results, and current treatment context. A Bone Scan Index can help quantify skeletal disease burden, but it does not establish a diagnosis by itself. It should be used as a supportive quantitative measure within a full clinical assessment.
The Bone Scan Index has its main value in oncology as a standardized way to quantify skeletal metastatic burden on bone scintigraphy. Rather than describing bone involvement only as “few,” “multiple,” or “extensive” lesions, BSI provides a numerical estimate that can be followed over time. Its best-established use is in metastatic prostate cancer, where bone is a common site of disease spread. A baseline BSI can document the extent of skeletal involvement before treatment, while serial BSI values may help show whether measurable bone disease burden is increasing, decreasing, or remaining stable.
BSI may also contribute to prognosis discussions and standardize imaging assessment in clinical research. However, it should not be used alone to define progression, response, or prognosis.
Prostate cancer commonly spreads to bone, particularly in advanced disease. Bone metastases may cause pain, fractures, spinal cord compression, anemia related to marrow involvement, or other complications, although some patients have no symptoms when skeletal disease is identified. BSI has been studied most extensively in metastatic prostate cancer, including metastatic castration-resistant prostate cancer. Compared with simply counting lesions, BSI may offer a more objective and standardized way to describe skeletal involvement.
Comparing BSI values across serial scans may help document whether measured skeletal tumour burden appears to decrease, remain stable, or increase during treatment. A lower BSI over time may be consistent with reduced measurable bone disease burden. A stable BSI may support stable skeletal disease. A rising BSI may suggest increasing skeletal involvement and should prompt careful review in the full clinical context.
BSI alone does not determine whether treatment is working. PSA kinetics, symptoms, performance status, laboratory results, treatment timing, and other imaging findings remain essential.
Automated BSI has been studied as an imaging biomarker in metastatic prostate cancer, particularly metastatic castration-resistant disease. In clinical trials, BSI may support patient stratification, eligibility assessment, prognostic modeling, and longitudinal evaluation of skeletal disease burden. A higher baseline BSI may identify patients with more extensive bone involvement, while change during therapy may provide an additional quantitative measure for exploratory response analyses. It is generally used as a supportive research biomarker rather than a standalone clinical-trial endpoint.
A lower Bone Scan Index generally indicates a lower estimated burden of skeletal metastatic disease, while a higher BSI generally reflects more extensive skeletal involvement on bone scintigraphy. There is no single “normal” BSI category that applies to every patient. The meaning of a value depends on cancer type, stage, scan timing, prior imaging, symptoms, PSA or other tumour-marker trends, and treatment history.
The most useful interpretation often comes from comparing BSI values over time rather than relying on one isolated score.
A low BSI suggests a smaller quantified burden of skeletal disease on the assessed bone scan. However, a low BSI does not always mean that disease is clinically insignificant. Even a limited number of bone metastases can be important depending on location, particularly in the spine, weight-bearing bones, or areas close to the spinal cord. Symptoms, fracture risk, neurologic concerns, treatment goals, PSA trends, and other imaging findings remain important when interpreting a low BSI result.
A high BSI suggests greater quantified skeletal involvement on the assessed bone scan. It indicates that a larger estimated proportion of total skeletal mass is affected by lesions considered suspicious for metastatic disease. In metastatic prostate cancer studies, higher BSI values have been associated with less favorable outcomes and may reflect more extensive bone metastatic burden. However, a high BSI alone does not determine an individual patient’s prognosis.
A rising BSI may suggest that quantified skeletal disease burden is increasing over time. A falling BSI may suggest a reduction in measurable skeletal disease burden on follow-up imaging. Scan timing matters. Healing bone, treatment-related flare, or other changes in bone turnover can temporarily increase uptake on bone scans even when a patient is benefiting from treatment. A rising or falling BSI should therefore never be interpreted in isolation.
Automated BSI has been studied as a prognostic imaging biomarker in metastatic castration-resistant prostate cancer. Research has found that a higher baseline BSI, and in some studies an increasing BSI over time, may be associated with poorer outcomes in groups of patients with metastatic disease. These findings support the role of BSI as a quantitative imaging measure that may add information beyond descriptive bone-scan reporting alone.
However, BSI is only one part of prognosis. PSA kinetics, visceral metastases, symptoms, performance status, hemoglobin and other laboratory findings, tumour biology, prior treatments, and treatment response all remain important.
Several studies have evaluated automated BSI as an independent prognostic factor for overall survival in metastatic castration-resistant prostate cancer. A higher baseline BSI, or an increase in BSI during follow-up, may be associated with shorter overall survival at the population level. However, these associations do not provide a guaranteed prediction for an individual patient.
A greater Bone Scan Index may reflect more extensive skeletal metastatic involvement and, in some patients, may be associated with a higher risk of bone-related symptoms or complications. Depending on disease context, a larger skeletal burden can be linked with bone pain, reduced mobility, fractures, spinal cord compression, or the need for supportive measures such as analgesia, bone-targeted therapy, palliative radiotherapy, or orthopedic evaluation.
BSI does not directly measure pain or function. Some patients with a higher BSI may have few symptoms, while others with a lower BSI may have clinically important pain because of lesion location.
A standard bone scan report is usually qualitative. It describes where abnormal areas of increased uptake are located, whether the pattern is suspicious for metastases, and the radiologist’s or nuclear medicine physician’s overall impression. The Bone Scan Index adds a quantitative layer. Rather than only describing the location and appearance of suspected lesions, BSI estimates the proportion of total skeletal mass affected by metastatic-appearing disease and expresses it as a numerical value.
A BSI tracker can make longitudinal documentation clearer by recording baseline and follow-up values in one place. However, it does not replace the original scan report, which remains essential for lesion location, interpretation of benign findings, and clinical context.
Qualitative reports may use terms such as new lesions, stable disease, increased uptake, improved uptake, or progression. These descriptions are clinically important, but interpretation can vary across readers and timepoints. Small changes may be difficult to describe consistently, especially when there are numerous lesions, overlapping uptake, or treatment-related bone changes.
BSI provides a numerical value that can be trended across serial assessments, making longitudinal documentation of skeletal disease burden clearer. For the most reliable comparison, the same validated BSI method or software platform should ideally be used for each scan. Different image-acquisition protocols, software algorithms, or reporting methods may affect comparability.
BSI should be interpreted alongside other cancer markers and clinical findings, not instead of them. In metastatic prostate cancer, BSI is commonly reviewed together with:
No single marker should independently determine whether disease is progressing or whether treatment should change.
PSA and Bone Scan Index measure different aspects of prostate cancer. PSA is a blood-based marker produced by prostate cells and may provide information about biochemical disease activity. BSI is an imaging-based estimate of skeletal metastatic burden. They may move in the same direction, but not always. PSA can decrease while bone scan activity temporarily rises because of flare or healing changes. Conversely, skeletal disease may progress despite only modest PSA changes in some patients.
BSI is derived from bone scintigraphy and provides a quantitative estimate of skeletal tumour burden. It does not replace CT, MRI, PSMA PET/CT, or other imaging when those studies are clinically indicated. CT and MRI may be needed to assess soft-tissue disease, lymph nodes, visceral metastases, spinal cord compression, fractures, or structural complications. PSMA PET/CT can provide more sensitive localization of prostate cancer lesions in selected settings.
Bone Scan Index tracking can provide a useful quantitative estimate of skeletal metastatic burden, but it is not a perfect or standalone measure of disease status. Its reliability depends on scan quality, image-acquisition technique, lesion detection, the software or calculation method used, and expert reader review. Comparing scores generated with different systems or imaging protocols may reduce the reliability of longitudinal interpretation.
Timing also matters. Bone scintigraphy reflects osteoblastic activity rather than tumour cells directly. Healing bone or flare after treatment can temporarily increase uptake, making disease appear more extensive even when treatment is helping. BSI may not be the most informative imaging approach for every patient. CT, MRI, PSMA PET/CT, or other modalities may be more appropriate when clinicians need to assess soft-tissue disease, visceral metastases, spinal complications, or equivocal bone findings.
Bone scan hotspots do not always represent metastatic disease. Arthritis, degenerative joint changes, recent fractures, inflammation, infection, postsurgical changes, and healing bone can all increase tracer uptake. This is why expert clinical review is essential. Nuclear medicine physicians and oncology teams consider hotspot location, pattern, prior scans, symptoms, tumour markers, treatment history, and additional imaging when needed.
After treatment begins, bone scans can sometimes appear worse before they improve. This is known as the flare effect. Because bone scintigraphy measures bone activity rather than cancer cells directly, increased uptake after treatment may reflect repair and healing rather than true disease progression. A temporary rise in BSI does not always mean that skeletal metastatic disease is worsening.
BSI values may differ depending on the software platform, image-acquisition protocol, hotspot-detection method, and interpretation approach used. Different tools may classify or quantify suspicious lesions differently. For longitudinal tracking, the same validated BSI method or software should ideally be used whenever possible.
The timing of BSI follow-up depends on cancer type, treatment plan, symptoms, prior imaging, and the oncology team’s monitoring protocol. A BSI may be documented at baseline before treatment begins, then reviewed at planned intervals to help assess the trend in skeletal disease burden. Follow-up may also be considered when symptoms change, PSA or other tumour markers rise, or clinicians need more information about possible progression or treatment response. There is no single schedule that applies to every patient. Imaging performed too soon after treatment begins may be affected by flare or healing-related changes in bone activity.
A baseline BSI is useful before starting a new treatment or changing an existing treatment plan because it provides a reference point for future comparison. Later scans can then be compared with the baseline to assess whether measured skeletal disease burden appears to increase, decrease, or remain stable.
Follow-up BSI assessments can help track changes in quantified skeletal disease burden over time. However, scan timing should follow the oncology team’s plan. It is usually based on cancer type, treatment regimen, symptoms, PSA or other tumour-marker trends, prior imaging, and concern for progression or treatment response.
New symptoms should be evaluated medically rather than waiting only for the next scheduled BSI comparison. New or worsening bone pain, reduced mobility, unexplained fractures, weakness, numbness, bowel or bladder changes, or other neurologic symptoms may require urgent assessment. A BSI tracker can support long-term documentation, but it should never delay evaluation of symptoms that may need immediate medical attention.
The Bone Scan Index tracker is mainly intended for clinicians, researchers, and informed patients who already have documented BSI values from a nuclear medicine report or validated image-analysis tool. It should not be used to self-diagnose bone metastases, estimate BSI from a scan image, or replace interpretation by a nuclear medicine physician, radiologist, or oncologist.
Clinicians can use the tracker to document current BSI, baseline BSI, and change over time in a clear longitudinal format. It is most useful when BSI values are recorded alongside original imaging reports, PSA or other laboratory trends, symptom assessments, performance status, treatment notes, and additional imaging results. The tracker can support structured follow-up discussions and treatment documentation, but it does not replace radiology reporting, multidisciplinary review, or clinical judgment.
Patients can use the Bone Scan Index tracker to better understand a BSI value that has already been discussed by their care team and to see how documented values have changed over time. A BSI score should not be interpreted alone. Patients should ask their oncologist, urologist, or nuclear medicine physician to explain what the value means in their individual case, including how it relates to symptoms, PSA results, treatment response, and other imaging findings. The tracker can support more informed conversations, but it cannot diagnose bone metastases or determine whether treatment is working.
